Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PrecipioPRPO +2.87%51 3-Year EPS without NRI Growth Rate is 60.00% as of Jun. 2026, which is 94% above its 10-year median of 31.00. GuruFocus rates PRPO with a GF Score™ of 51/100 and a GF Value™ of $10.59 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 158 Medical Diagnostics & Research companies, Precipio ranks better than 89.24% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 60.00% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 42.60% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 58.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Precipio was 77.70% per year. The lowest was -178.50% per year. And the median was 31.00% per year.
Precipio (NAS:PRPO) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Precipio 3-Year EPS without NRI Growth Rate Related Terms
PRPO vs IDXG, ADVB, BIOQ: 3-Year EPS without NRI Growth Rate Comparison
For the Diagnostics & Research subindustry, Precipio's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Precipio 3-Year EPS without NRI Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Precipio's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Precipio's 3-Year EPS without NRI Growth Rate falls into.
Precipio 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 60.00% mean?
Precipio (PRPO) has a 3-Year EPS without NRI Growth Rate of 60.00% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Precipio and its competitors. This is 94% above median its historical median of 31.00. According to the industry distribution chart, Precipio ranks #17 out of 158 companies in the Medical Diagnostics & Research industry, placing it in the top 10.8%.
Is Precipio's 3-Year EPS without NRI Growth Rate too high?
Precipio's current 3-Year EPS without NRI Growth Rate of 60.00% is 94% above median its 10-year median of 31.00. The Medical Diagnostics & Research industry median 3-Year EPS without NRI Growth Rate is 10.75. Precipio's value of 60.00% is 458.1% above this industry median. Based on the distribution chart, Precipio ranks #17 out of 158 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Precipio has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Precipio's 3-Year EPS without NRI Growth Rate compare to IDXG and ADVB?
According to the Medical Diagnostics & Research industry distribution chart, Precipio ranks #17 out of 158 companies for 3-Year EPS without NRI Growth Rate. This places Precipio in the top 11% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 10.75. Precipio's value of 60.00% is 458.1% above this benchmark. While the company's 10-year median is 31.00 vs. the industry median of 10.75, Precipio has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year EPS without NRI Growth Rate among Medical Diagnostics & Research companies is 10.75, based on 158 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Precipio's current 3-Year EPS without NRI Growth Rate of 60.00% is 458.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Precipio and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year EPS without NRI Growth Rate is 10.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Precipio's current 3-Year EPS without NRI Growth Rate is 60.00%, which is 94% above median its own 10-year median of 31.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Precipio stock overvalued right now?
Based on GuruFocus' analysis, Precipio (PRPO) is currently considered Significantly Overvalued. The stock's GF Value™ is $10.59, compared to a current price of $30.17 — trading 184.9% above its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 60.00%, which is 94% above median its 10-year median of 31.00 and 458.1% above the Medical Diagnostics & Research industry median of 10.75. Precipio's overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Precipio (PRPO), the current 3-Year EPS without NRI Growth Rate is 60.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Precipio (PRPO) Overvalued in 2026?
Based on GuruFocus' analysis, Precipio stock appears to be overvalued.
The current stock price of $30.17 is trading 184.9% above its estimated GF Value™ of $10.59.
GuruFocus considers Precipio to be Significantly Overvalued.
Key valuation signals for PRPO:
3-Year EPS without NRI Growth Rate: 60.00% (94% above median its 10-year median of 31.00)
GF Value™: $10.59 vs. price of $30.17 (184.9% above fair value)
Industry Position: 458.1% above the Medical Diagnostics & Research median (#17 of 158)
No single metric tells the full story. See the PRPO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, & Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division & the Products Division. The Pathology Services provides specialized cancer diagnostic testing services. The pathology services division specializes in diagnostic testing focused mainly on hematologic cancers.
51GF Score
Get the complete analysis for PRPO
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRPO has been successfully added to your 
